X4 Pharmaceuticals, Inc. - Common Stock — 재무제표 (NASDAQ:XFOR) | MetaTrader

전체 차트 열기 Full chart

Financials

개요 성명 통계

총자산 122.87 M117.18 M155.59 M147.26 M146.45 M290.46 M 총 부채 50.07 M52.76 M81.53 M96.16 M124.3 M104.17 M 자본금 총액 72.8 M64.41 M74.05 M51.1 M22.15 M186.29 M 총 부채 및 주주자본 122.87 M117.18 M155.59 M147.26 M146.45 M290.46 M 총부채 —33.14 M32.3 M54.57 M—— 순부채 —33.14 M32.3 M-59.63 M——

뉴스

Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Now

X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should Know

X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates

Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates

스티펠, X4 파마슈티컬스 주식 투자의견 재확인

X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates

ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates

X4 파마슈티컬스, 희귀 혈액 질환으로 전략 전환

X4 Pharmaceuticals at Leerink Global Healthcare Conference: Strategic Shift to Rare Hematology

Guggenheim initiates X4 Pharmaceuticals stock with buy rating

X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval

EMA, 초희귀 WHIM 증후군 치료제 ’마보릭사포르’ 승인 권고